Academic Journal
Q1Lancet Infectious Diseases
About Lancet Infectious Diseases
Lancet Infectious Diseases is a scholarly journal published by Elsevier Ltd. SCImago 2025 places it in Q1 with an SJR of 5.549 and an H-index of 317.
Its listed coverage is 2001-2026 and its research categories include Infectious Diseases (Q1). The 2025 dataset reports 453 documents and 11316 citations across the latest three-year reporting window.
The Lancet Infectious Diseases is one of the most respected and widely cited journals in the field of infectious diseases. As part of the prestigious Lancet family of medical journals, it plays a vital role in advancing global health by publishing cutting-edge research, expert reviews, and insightful commentary on the prevention, diagnosis, and treatment of infectious diseases.
Founded in 2001, The Lancet Infectious Diseases has established itself as a premier source for peer-reviewed content focused on the science and clinical management of infections. With a high impact factor and a reputation for excellence, the journal attracts contributions from leading researchers, clinicians, and public health experts from around the world.
Scope and Coverage
The journal covers a broad spectrum of topics related to infectious diseases, including:
-
Epidemiology of infectious diseases
-
Microbial pathogenesis
-
Antimicrobial resistance
-
Vaccine development and implementation
-
Global outbreaks and emerging infections
-
Clinical trials and treatment strategies
Whether it's tracking the evolution of novel pathogens like COVID-19 or offering insights into the containment of long-standing threats such as tuberculosis and malaria, The Lancet Infectious Diseases delivers timely, evidence-based content that informs both clinical practice and health policy.
Why The Lancet Infectious Diseases Matters
In a world where infectious diseases can rapidly cross borders and disrupt societies, timely access to reliable scientific information is more important than ever. The Lancet Infectious Diseases serves as a trusted platform for disseminating crucial research and promoting collaboration across disciplines and geographies.
The journal’s articles often influence policy decisions, clinical guidelines, and public health strategies. During the COVID-19 pandemic, for example, its publications played a critical role in guiding responses at both national and international levels.
Peer Review and Editorial Standards
All submissions to The Lancet Infectious Diseases undergo a rigorous peer-review process to ensure scientific accuracy, originality, and relevance. The editorial board includes prominent experts in infectious diseases, microbiology, epidemiology, and immunology, ensuring that published content meets the highest standards of quality.
The journal is indexed in major databases such as PubMed, Scopus, and Web of Science, making it easily discoverable by researchers, clinicians, and students worldwide.
Global Reach and Accessibility
With a global readership and a commitment to open access for selected articles, The Lancet Infectious Diseases supports equitable access to scientific knowledge. The journal regularly publishes themed issues and country-focused series to highlight regional challenges and advancements in infectious disease control.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
When it comes to authoritative sources in the field of infectious diseases, The Lancet Infectious Diseases stands at the forefront of global medical research and public health discourse. This prestigious peer-reviewed journal, part of the renowned Lancet family of publications, is a critical resource for researchers, clinicians, policymakers, and healthcare professionals alike. Its extensive scope, commitment to scientific excellence, and global reach make it a cornerstone in the fight against infectious diseases.
What Is The Lancet Infectious Diseases?
Founded in 2001, The Lancet Infectious Diseases is a monthly journal that focuses on all aspects of infectious diseases in humans. It publishes high-impact research articles, reviews, editorials, and commentary pieces on topics ranging from epidemiology and microbiology to emerging pathogens, antimicrobial resistance, vaccine development, and clinical practice.
Key Areas of Focus
The journal's scope is both broad and detailed, encompassing a wide range of infectious disease-related topics, including:
-
Emerging Infectious Diseases: From SARS-CoV-2 to Zika and Ebola, the journal regularly publishes cutting-edge research on novel pathogens and global outbreak responses.
-
Antimicrobial Resistance (AMR): As one of the greatest public health threats of the 21st century, AMR is a recurring theme in the journal’s publications.
-
Vaccinology and Immunization: Articles explore vaccine efficacy, public health implementation, and immunization strategies in diverse populations.
-
Clinical Practice: The journal features clinical trials, case studies, and treatment guidelines relevant to infectious disease physicians and specialists.
-
Global Health: There is a strong emphasis on health equity and infectious disease challenges in low- and middle-income countries.
Why It Matters
The Lancet Infectious Diseases plays a crucial role in shaping health policy and clinical guidelines. Its rigorous peer-review process and editorial oversight ensure that the research published is of the highest quality. For anyone involved in infectious disease research or practice, staying up to date with the journal’s latest publications is essential.
Moreover, the journal often collaborates with major health organizations, including the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and academic institutions worldwide. This positions it as not only a publication platform but also a central node in the global health research network.
Accessibility and Readership
With a robust online platform and indexed in major medical databases like PubMed and Scopus, The Lancet Infectious Diseases reaches a global audience. The journal’s content is widely cited and has a high impact factor, making it a trusted source in academic and clinical settings.
Recent Research Articles
Latest publications matched automatically by ISSN.
Tularaemia after deer exposure in a vehicular collision
Henning Gruell, Benedict Steffens, Daniela Jacob, Thorsten Wille et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00297-5Dihydroartemisinin–piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, single-centre, randomised clinical trial
Djane C Baía-da-Silva, Kim Vinícius AmaralC Machado, Amanda Lia RebêloC Rabelo, Antônio AlcirleyC da Silva Balieiro et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00139-8Cefiderocol heteroresistance in NDM Enterobacterales
Tugba Ozturk, Sarah Lohsen, Sarah W Satola, David S Weiss et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00317-8Diagnostic performance of RADIONE for diagnosis of BDBV
Tony Wawina-Bokalanga, Adrienne Amuri-Aziza, Koen Vercauteren, Daniel Mukadi-Bamuleka et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00321-xArtemisinin partial resistance at a crossroads: evidence for continental variation in Plasmodium falciparum clearance phenotypes
Varun Hosangadi, David A Fidock
2026-09 · DOI: 10.1016/s1473-3099(26)00132-5New UN resolution links NTDs to human rights
Timothy Jesudason
2026-09 · DOI: 10.1016/s1473-3099(26)00422-6SARS-CoV-2 BA.3.2.2 is more evasive of neutralisation by plasma from young children
Madeline Wu, Hsiang Hong, Yicheng Guo, Kristin Daniel et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00349-xRing and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study
Jason R Andrews, Placide K Mbala, Patrick K Mukadi, Jason Kindrachuk et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00464-0Immunogenicity and safety of a dose-sparing inactivated poliovirus vaccine in infants in India: a phase 2/3, double-blind, randomised controlled trial
Prasad S Kulkarni, Sajjad A Desai, Suman Kanungo, Shanta Dutta et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00108-8Correction to Lancet Infect Dis 2020; 20: 60–79
2026-09 · DOI: 10.1016/s1473-3099(26)00376-2USA to end support of South Africa's HIV programmes
Ed Holt
2026-09 · DOI: 10.1016/s1473-3099(26)00416-0Global and regional molecular epidemiology of HIV-1 during 1990–2024: systematic review, global survey, and analysis of prevalence
Ayisha Khalid, Lucy Gettins, Lauren Scullion, Xin Liu et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00142-8South Sudan's first 100 days of Bundibugyo Ebola readiness
Dick Chamla, Marie Roseline Darnycka Belizaire, Arisekola Jinadu, Aggrey Bategereza et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00480-9Oral carbapenem—a double-edged sword?
The Lancet Infectious Diseases
2026-09 · DOI: 10.1016/s1473-3099(26)00430-5Accelerated qualification of diagnostic tests during an ongoing outbreak of Bundibugyo virus disease: a collaborative analytical validation study
Till Dominik Best, Lisa Oestereich, Francesca Colavita, Janine Michel et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00465-2Aalisha Sahukhan—strengthening public health responses
Tony Kirby
2026-09 · DOI: 10.1016/s1473-3099(26)00431-7First rapid nucleic acid test for Bundibugyo virus
Priya Venkatesan
2026-09 · DOI: 10.1016/s1473-3099(26)00426-3Correction to Lancet Infect Dis 2026; published online June 30. https://doi.org/10.1016/S1473-3099(26)00256-2
2026-09 · DOI: 10.1016/s1473-3099(26)00415-9Pseudovirus-based analysis of host cell entry and vaccine-induced neutralisation of Bundibugyo virus
Markus Hoffmann, Aparna Shandheep, Andreas Pavlou, Katharina Rahmel-Stein et al.
2026-09 · DOI: 10.1016/s1473-3099(26)00407-xEnrolment begins in the EBO-PEP trial in DRC
Talha Burki
2026-09 · DOI: 10.1016/s1473-3099(26)00427-5Reviews
Community Reviews
Version History
April 19, 2025 at 4:53 pm
April 19, 2025